Preskoči na sadržaj
Korištenjem servisa na Twitteru pristajete na korištenje kolačića. Twitter i partneri rade globalno te koriste kolačiće za analize, personalizaciju i oglase.

Za najbolje sučelje na Twitteru koristite Microsoft Edge ili instalirajte aplikaciju Twitter iz trgovine Microsoft Store.

  • Naslovnica Naslovnica Naslovnica, trenutna stranica.
  • O Twitteru

Spremljena pretraživanja

  • obriši
  • U ovom razgovoru
    Ovjeren akauntZaštićeni tweetovi @
Predloženi korisnici
  • Ovjeren akauntZaštićeni tweetovi @
  • Ovjeren akauntZaštićeni tweetovi @
  • Jezik: Hrvatski
    • Bahasa Indonesia
    • Bahasa Melayu
    • Català
    • Čeština
    • Dansk
    • Deutsch
    • English
    • English UK
    • Español
    • Filipino
    • Français
    • Italiano
    • Magyar
    • Nederlands
    • Norsk
    • Polski
    • Português
    • Română
    • Slovenčina
    • Suomi
    • Svenska
    • Tiếng Việt
    • Türkçe
    • Български език
    • Русский
    • Српски
    • Українська мова
    • Ελληνικά
    • עִבְרִית
    • العربية
    • فارسی
    • मराठी
    • हिन्दी
    • বাংলা
    • ગુજરાતી
    • தமிழ்
    • ಕನ್ನಡ
    • ภาษาไทย
    • 한국어
    • 日本語
    • 简体中文
    • 繁體中文
  • Imate račun? Prijava
    Imate račun?
    · Zaboravili ste lozinku?

    Novi ste na Twitteru?
    Registrirajte se
Profil korisnika/ce bengoldacre
ben goldacre
ben goldacre
ben goldacre
Ovjeren akaunt
@bengoldacre

Tweets

ben goldacreOvjeren akaunt

@bengoldacre

Doctor, nerd cheerleader, Bad Science person, stats geek, procrastinator. I run http://ebmdatalab.net  at @uniofoxford making tools+papers from data ben@badscience.net

Oxford, England
badscience.net
Vrijeme pridruživanja: lipanj 2007.

Tweets

  • © 2020 Twitter
  • O Twitteru
  • Centar za pomoć
  • Uvjeti
  • Pravila o privatnosti
  • Imprint
  • Kolačići
  • Informacije o oglasima
Odbaci
Prethodni
Sljedeće

Idite na profil osobe

Spremljena pretraživanja

  • obriši
  • U ovom razgovoru
    Ovjeren akauntZaštićeni tweetovi @
Predloženi korisnici
  • Ovjeren akauntZaštićeni tweetovi @
  • Ovjeren akauntZaštićeni tweetovi @

Odjava

Blokiraj

  • Objavi Tweet s lokacijom

    U tweetove putem weba ili aplikacija drugih proizvođača možete dodati podatke o lokaciji, kao što su grad ili točna lokacija. Povijest lokacija tweetova uvijek možete izbrisati. Saznajte više

    Vaši popisi

    Izradi novi popis


    Manje od 100 znakova, neobavezno

    Privatnost

    Kopiraj vezu u tweet

    Ugradi ovaj Tweet

    Embed this Video

    Dodajte ovaj Tweet na svoje web-mjesto kopiranjem koda u nastavku. Saznajte više

    Dodajte ovaj videozapis na svoje web-mjesto kopiranjem koda u nastavku. Saznajte više

    Hm, došlo je do problema prilikom povezivanja s poslužiteljem.

    Integracijom Twitterova sadržaja u svoje web-mjesto ili aplikaciju prihvaćate Twitterov Ugovor za programere i Pravila za programere.

    Pregled

    Razlog prikaza oglasa

    Prijavi se na Twitter

    · Zaboravili ste lozinku?
    Nemate račun? Registrirajte se »

    Prijavite se na Twitter

    Niste na Twitteru? Registrirajte se, uključite se u stvari koje vas zanimaju, i dobivajte promjene čim se dogode.

    Registrirajte se
    Imate račun? Prijava »

    Dvosmjerni (slanje i primanje) kratki kodovi:

    Država Kod Samo za korisnike
    Sjedinjene Američke Države 40404 (bilo koje)
    Kanada 21212 (bilo koje)
    Ujedinjeno Kraljevstvo 86444 Vodafone, Orange, 3, O2
    Brazil 40404 Nextel, TIM
    Haiti 40404 Digicel, Voila
    Irska 51210 Vodafone, O2
    Indija 53000 Bharti Airtel, Videocon, Reliance
    Indonezija 89887 AXIS, 3, Telkomsel, Indosat, XL Axiata
    Italija 4880804 Wind
    3424486444 Vodafone
    » Pogledajte SMS kratke šifre za druge zemlje

    Potvrda

     

    Dobro došli kući!

    Vremenska crta mjesto je na kojem ćete provesti najviše vremena i bez odgode dobivati novosti o svemu što vam je važno.

    Tweetovi vam ne valjaju?

    Prijeđite pokazivačem preko slike profila pa kliknite gumb Pratim da biste prestali pratiti neki račun.

    Kažite mnogo uz malo riječi

    Kada vidite Tweet koji volite, dodirnite srce – to osobi koja ga je napisala daje do znanja da vam se sviđa.

    Proširite glas

    Najbolji je način da podijelite nečiji Tweet s osobama koje vas prate prosljeđivanje. Dodirnite ikonu da biste smjesta poslali.

    Pridruži se razgovoru

    Pomoću odgovora dodajte sve što mislite o nekom tweetu. Pronađite temu koja vam je važna i uključite se.

    Saznajte najnovije vijesti

    Bez odgode pogledajte o čemu ljudi razgovaraju.

    Pratite više onoga što vam se sviđa

    Pratite više računa da biste dobivali novosti o temama do kojih vam je stalo.

    Saznajte što se događa

    Bez odgode pogledajte najnovije razgovore o bilo kojoj temi.

    Ne propustite nijedan aktualni događaj

    Bez odgode pratite kako se razvijaju događaji koje pratite.

    ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
    • Prijavi Tweet

    BING BONG NEW PAPER @NDevito1 @sebbacon and me in the LANCET today. We definitively assess compliance with US law FDAAA 2007, which requires clinical trials to report results within 12 months of completion. The answer: 59% of trials breached the lawhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33220-9/fulltext …

    16:00 - 17. sij 2020.
    • 299 proslijeđenih tweetova
    • 488 oznaka „sviđa mi se”
    • David Cottam Glowree Michael Paver Anna Noel-Storr bonnie m circuitloop partwave∴ Bridgette York Fibroid New Research
    7 replies 299 proslijeđenih tweetova 488 korisnika označava da im se sviđa
      1. Novi razgovor
      2. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        This was a truly epic piece of work. We parsed the law. We converted it into unambiguous logic. We built software to download all US trial data and apply that logic. We stored snapshots for time trends. We built regression models to help spot patterns. Because of that we can say:

        13 proslijeđenih tweetova 56 korisnika označava da im se sviđa
        Prikaži ovu nit
      3. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        Compliance with this law is very poor. But it is also *staying* poor: it is not improving over time. You can see for yourself in the blue line on this graph. That is very concerning. Why has there been no improvement? One key issue is likely to be enforcement...pic.twitter.com/ebEugDSYYV

        1 reply 14 proslijeđenih tweetova 46 korisnika označava da im se sviđa
        Prikaži ovu nit
      4. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        ... or rather, the absence of enforcement. @US_FDA is entitled to impose fines of up to $10,000 a day on non-compliant trial sponsors (that's now been inflation-adjusted to $12,103 a day). We calculate @US_FDA could have imposed $4bn in fines. They have never fined anyone, ever..

        1 reply 25 proslijeđenih tweetova 49 korisnika označava da im se sviđa
        Prikaži ovu nit
      5. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        Of course we look at who is more, and less, likely to comply with the law on reporting trial results. Here's a funny thing. For many years the pharmaceutical industry poo-pooed efforts to get all trials reported. There was much funny business. But now that the law is passed?...

        9 proslijeđenih tweetova 26 korisnika označava da im se sviđa
        Prikaži ovu nit
      6. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        ... drug companies are much better at complying than non-industry trialists. Why is that? It's hardly hard. Companies might lobby, energetically, against rules; they might hunt for loopholes, skillfully; but after that they also... competently follow those rules...

        10 proslijeđenih tweetova 41 korisnik označava da mu se sviđa
        Prikaži ovu nit
      7. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        Competence is an interesting phenomenon to explore. Data scientists and data journalists might be interested in this next bit. Anyone can produce a paper or a finding with a vast budget. But research, and data analysis, is usually much more like a game of "scrapheap challenge"...

        1 reply 6 proslijeđenih tweetova 26 korisnika označava da im se sviđa
        Prikaži ovu nit
      8. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        We have concocted a cunning new explanatory variable for these analyses to explore competence and experience among trialists. For every trial sponsor, we counted how many trials they have on the register in total. We split this into quarters. Now....

        1 reply 5 proslijeđenih tweetova 15 korisnika označava da im se sviđa
        Prikaži ovu nit
      9. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        .. this means we now have four groups of trials: trials run by organisations that do LOADS of trials; trials done by small-scale chancers who have only done a few trials ever; dnd two groups in between. Magic! New insights! For free! And the answer?...

        1 reply 4 proslijeđena tweeta 17 korisnika označava da im se sviđa
        Prikaži ovu nit
      10. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        ... Sponsors who do LOADS of trials are SPECTACULARLY more likely to comply with the rules on reporting results. (I think they're more likely to be competent in other ways too.. but that's for another paper).

        1 reply 7 proslijeđenih tweetova 32 korisnika označavaju da im se sviđa
        Prikaži ovu nit
      11. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        We thought it would be helpful to give performance data for individual organisations. Here are the ten sponsors with the most trials on the register. Credit where it is due: we should praise the drug companies listed for complying so well with the law. By contrast...pic.twitter.com/DQM8CgiWoz

        1 reply 14 proslijeđenih tweetova 33 korisnika označavaju da im se sviđa
        Prikaži ovu nit
      12. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        It is remarkable to see @MassGeneralNews, Harvard Medical School, breaching FDA laws on clinical trial reporting so commonly: only 32/58 due trials from them complied with the law. @UCSF has the worse compliance: just 6/38 due clinical trials complied.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33220-9/fulltext …

        1 reply 10 proslijeđenih tweetova 33 korisnika označavaju da im se sviđa
        Prikaži ovu nit
      13. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        So why does this all matter? Simple. Clinical trials are not abstract research projects. We use trials to produce the treatment guidelines used on all patients every day. Doctors and patients cannot make informed choices about which treatments to use when results are withheld.

        1 reply 11 proslijeđenih tweetova 45 korisnika označava da im se sviđa
        Prikaži ovu nit
      14. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        Patients participate in clinical trials because we tell them (often explicitly in consent forms) that their participation will produce new evidence to improve treatment for all patients. When we fail to report results, we break that promise, and we breach patients' trust.

        1 reply 12 proslijeđenih tweetova 60 korisnika označava da im se sviđa
        Prikaži ovu nit
      15. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        So, why should you trust our paper, and our findings? Because we did it right. We share our methods from beginning to end. We also share our entire codebase, to download and process the data, for review and re-use under open licenses. Go see:https://github.com/ebmdatalab/fdaaa_trends …

        1 reply 10 proslijeđenih tweetova 52 korisnika označavaju da im se sviđa
        Prikaži ovu nit
      16. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        ben goldacre je proslijedio/a tweet korisnika/ceben goldacre

        If you'd like to know more about why researchers should ALWAYS share their analytic code (and how often they fail, or even refuse to do so) see our recent @bmj_latest editorial on the topic.https://twitter.com/bengoldacre/status/1197482152151175168 …

        ben goldacre je dodan/na,

        ben goldacreOvjeren akaunt @bengoldacre
        * BING BONG * A new BMJ EDITORIAL from my team. WHY RESEARCHERS SHOULD SHARE THEIR ANALYTIC CODE Non-paywall link below. NOW this is VERY IMPORTANT stuff for safety, efficiency, reproducibility and quality in research, data science, and evidence… https://www.bmj.com/content/367/bmj.l6365.full?ijkey=gqrhcfWkUzCtdjE&keytype=ref …
        Prikaži ovu nit
        1 reply 9 proslijeđenih tweetova 22 korisnika označavaju da im se sviđa
        Prikaži ovu nit
      17. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        Lastly, if you want to see whether your organisation has reported all its trials, and complied with the law, we share live updating data here http://fdaaa.trialstracker.net/ 

        1 reply 6 proslijeđenih tweetova 23 korisnika označavaju da im se sviđa
        Prikaži ovu nit
      18. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        We do this because we want to help those who want to comply, and change the incentives around papers like this. When you publish a one-off journalistic piece, or paper, then organisations who have failed to comply with the law are incentivised to tough it out...

        1 reply 2 proslijeđena tweeta 11 korisnika označava da im se sviđa
        Prikaži ovu nit
      19. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        ...issue a statement "we take these matters very seriously...", maybe try to pick some minor holes or muddy the waters on some of the numbers, but overall, you're trying to survive the week until the critical numbers go away. We provide a better route for organisations: improve.

        1 reply 2 proslijeđena tweeta 10 korisnika označava da im se sviđa
        Prikaži ovu nit
      20. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        .. If any organisation is concerned by their poor performance in this data, or this paper, they can simply report their trials, and they will immediately rise to the top of the league tables. Our data updates EVERY working day...

        1 reply 2 proslijeđena tweeta 15 korisnika označava da im se sviđa
        Prikaži ovu nit
      21. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        .. and this isn't theoretical. Our http://trialstracker.net  tools make it easy for good people to do the right thing, and here are examples of good people doing the right thing, using our data: https://ebmdatalab.net/our-fdaaa-trialstracker-is-already-helping-to-get-new-trials-reported/ … We assume good faith, and we are not disappointed.

        1 reply 5 proslijeđenih tweetova 18 korisnika označava da im se sviđa
        Prikaži ovu nit
      22. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        So! Please do read + share our paper, it's written to be accessible for all! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33220-9/fulltext … Sign http://alltrials.net  Check http://fdaaa.trialstracker.net  And huge thanks to @JohnArnoldFndtn for funding my transparency work, and @GoodThinkingSoc for funding the trackers!

        11 proslijeđenih tweetova 29 korisnika označava da im se sviđa
        Prikaži ovu nit
      23. ben goldacre‏Ovjeren akaunt @bengoldacre 18. sij
        • Prijavi Tweet

        Nice coverage by @reuters for our new Lancet paper out today, showing major US universities (and companies) failing to comply with @us_fda rules on reporting clinical trial results. And FDA, in turn, failing to enforce the law. https://www.reuters.com/article/us-health-research-reporting/despite-us-law-many-clinical-trial-results-go-unreported-idUSKBN1ZG2L0 … https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33220-9/fulltext …

        25 proslijeđenih tweetova 50 korisnika označava da im se sviđa
        Prikaži ovu nit
      24. Kraj razgovora

    Čini se da učitavanje traje već neko vrijeme.

    Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

      Sponzorirani tweet

      false

      • © 2020 Twitter
      • O Twitteru
      • Centar za pomoć
      • Uvjeti
      • Pravila o privatnosti
      • Imprint
      • Kolačići
      • Informacije o oglasima